Mohamed Hamdani
Overview
Explore the profile of Mohamed Hamdani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
743
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Clayton R, Galas T, Scherer N, Farmer J, Ruiz N, Hamdani M, et al.
Ann Clin Transl Neurol
. 2024 Feb;
11(3):540-553.
PMID: 38311797
Objective: Current treatments for Friedreich's ataxia, a neurodegenerative disorder characterized by decreased intramitochondrial frataxin, do not address low frataxin concentrations. Nomlabofusp (previously CTI-1601) is a frataxin replacement therapy with a...
2.
Alahiane M, Oukhrib R, Ait Albrimi Y, Abou Oualid H, Bourzi H, Akbour R, et al.
RSC Adv
. 2022 May;
10(67):41137-41153.
PMID: 35519220
The inhibition efficiency of benzoic acid (C1), -hydroxybenzoic acid (C2), and 3,4-dihydroxybenzoic acid (C3) towards enhancing the corrosion resistance of austenitic AISI 316 stainless steel (SS) has been evaluated in...
3.
Titchou F, Zazou H, Afanga H, Jamila E, Akbour R, Hamdani M, et al.
Environ Res
. 2021 Nov;
204(Pt D):112353.
PMID: 34774509
This study aims to compare the efficiency of anodic oxidation with electrogenerated HO (AO-HO), electro-Fenton (EF), and their association with UV irradiation (photo anodic oxidation (PAO), and photo electro-Fenton (PEF)...
4.
Hillmen P, Szer J, Weitz I, Roth A, Hochsmann B, Panse J, et al.
N Engl J Med
. 2021 Mar;
384(11):1028-1037.
PMID: 33730455
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disease characterized by chronic complement-mediated hemolysis. C5 inhibition controls intravascular hemolysis in untreated PNH but cannot address extravascular hemolysis. Pegcetacoplan, a...
5.
Steinle N, Pearce I, Mones J, Metlapally R, Saroj N, Hamdani M, et al.
Am J Ophthalmol
. 2021 Mar;
227:116-124.
PMID: 33675755
Purpose: To evaluate the effect of select baseline characteristics on geographic atrophy (GA) progression in eyes receiving intravitreal pegcetacoplan or sham. Design: Phase 2 multicenter, randomized, single-masked, sham-controlled trial. Methods:...
6.
Benlouali H, Karmal I, Cherif Harrouni M, Ghanbaja J, Frascari D, Hamdani M, et al.
Water Sci Technol
. 2021 Jan;
83(2):309-321.
PMID: 33504696
In Agadir, a water-scarce Moroccan region, municipal and industrial wastewater is tertiary-treated to be reused in golf courses. Wastewater reuse has been constrained by severe clogging of emitters, which caused...
7.
Horsch S, Parodi A, Hallberg B, Malova M, Bjorkman-Burtscher I, Hansen-Pupp I, et al.
Front Pediatr
. 2020 Nov;
8:517207.
PMID: 33163463
Postnatal insulin-like growth factor-1 (IGF-1) replacement with recombinant human (rh)IGF-1 and IGF binding protein-3 (rhIGF-1/rhIGFBP-3) is being studied as a potential treatment to reduce comorbidities of prematurity. We have recently...
8.
Liao D, Grossi F, El Mehdi D, Gerber M, Brown D, Heier J, et al.
Ophthalmology
. 2019 Sep;
127(2):186-195.
PMID: 31474439
Purpose: Geographic atrophy (GA), a late stage of age-related macular degeneration (AMD), is a major cause of blindness. Even while central visual acuity remains relatively well preserved, GA often causes...
9.
Ley D, Hallberg B, Hansen-Pupp I, Dani C, Ramenghi L, Marlow N, et al.
J Pediatr
. 2018 Nov;
206:56-65.e8.
PMID: 30471715
Objective: To investigate recombinant human insulin-like growth factor 1 complexed with its binding protein (rhIGF-1/rhIGFBP-3) for the prevention of retinopathy of prematurity (ROP) and other complications of prematurity among extremely...
10.
Nichols K, Holland E, Toyos M, Peace J, Majmudar P, Raychaudhuri A, et al.
Clin Ophthalmol
. 2018 Feb;
12:263-270.
PMID: 29440868
Purpose: To evaluate ocular comfort of lifitegrast ophthalmic solution 5.0% among patients with dry eye disease (DED) in the OPUS-3 trial. Methods: OPUS-3 was a multicenter, randomized, double-masked, placebo-controlled study....